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ABSTRACT
Necrotic bone exposure in the oral cavity has recently been reported in patients treated with nitrogen-containing bisphosphonates as
part of their therapeutic regimen for multiple myeloma or metastatic cancers to bone. It has been postulated that systemic conditions
associated with cancer patients combined with tooth extraction may increase the risk of osteonecrosis of the jaw (ONJ). The objective of
this study was to establish an animal model of bisphosphonate-related ONJ by testing the combination of these risk factors. The
generation of ONJ lesions in rats resembling human disease was achieved under the confluence of intravenous injection of zoledronate
(ZOL; 35mg/kg every 2 weeks), maxillary molar extraction, and vitamin D deficiency [VitD()]. The prevalence of ONJ in the VitD()/ZOL
group was 66.7%, which was significantly higher (p< .05, Fisher exact test) than the control (0%), VitD() (0%), and ZOL alone (14.3%)
groups. Similar to human patients, rat ONJ lesions prolonged the oral exposure of necrotic bone sequestra and were uniquely associated
with pseudoepitheliomatous hyperplasia. The number of terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate–
biotin nick-end label–positive (TUNELþ) osteoclasts significantly increased on the surface of post–tooth extraction alveolar bone of the
VitD()/ZOL group, where sustained inflammation was depicted by [18F]fluorodeoxyglucose micro-positron emission tomography
(mPET). ONJ lesions were found to be associated with dense accumulation of mixed inflammatory/immune cells. These cells, composed
of neutrophils and lymphocytes, appeared to juxtapose apoptotic osteoclasts. It is suggested that the pathophysiologic mechanism(s)
underpinning ONJ may involve the interaction between bisphosphonates and compromised vitamin D functions in the realm of skeletal
homeostasis and innate immunity.  2010 American Society for Bone and Mineral Research.
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Nitrogen-containing bisphosphonates (BPs), synthetic analo-gues of pyrophosphate, are effective in treatment of
hypercalcemia of malignancy, osteolytic lesions in multiple
myeloma, and bone metastases from solid tumors, including
breast cancer and hormone-independent prostate cancer.(1)
Serious complications are relatively rare (ranging from 0.1% to
1.8%) but include acute systemic inflammatory reaction, renal
failure, and electrolyte imbalance.(2) However, a new concern is
raised by the recent reports of osteonecrosis of the jaw (ONJ) in
patients treated with these drugs.(3–5) Estimates of the cumul-
ative incidence of ONJ from retrospective case reports andReceived in original form April 8, 2009; revised form November 9, 2009; accepted
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 2010 American Society for Bone and Mineral Researchreviews(5–8) are as high as 10% among patients treated with BP
intravenous infusions. The problem is not gender-specific and
occurs in the mandible, maxilla, or both jaws.(5) In addition, oral
BPs are currently the most widely used agents for the prevention
and treatment of osteoporosis, although they are used at much
lower bioavailable doses. While conclusive prevalence data in
this patient group are not yet available, ONJ has begun to be
recognized in a limited number of subjects receiving oral BPs.(9)
The American Society for Bone and Mineral Research (ASBMR)
Task Force proposed the provisional case definition of ONJ as an
area of exposed bone in themaxillofacial region that did not heal
within 8 weeks in a patient who had been exposed to BPs.(10) ONJ
typically is described as a failure of wound healing in the oralDecember 29, 2009. Published online January 14, 2010.
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cavity or as severe, unresolved periodontal inflammation leading
to necrotic bone exposure.(5,8,11) Tooth extraction is the highest
risk factor for patients receiving BPs to develop ONJ. Kyrgidis and
colleagues (2008) reported a case-control study in which tooth
extraction during BP treatment significantly increased the risk
(adjusted odds ratio of 16.4) of developing ONJ.(12) The ASBMR
Task Force has further pointed out that there may be systemic
risk factors related to cancer treatments.(10) It has been
suggested that concurrent chemotherapy and dexamethasone
may increase the risk of developing ONJ.(9) Sonis and colleagues
(2009) reported ONJ-like lesions after tooth extraction in rats
treated with zoledronate and dexamethasone.(13) However, the
mechanism linking these risk factors to the development of ONJ
has not been established.
Most ONJ lesions are observed in patients presenting a
primary diagnosis of multiple myeloma or breast cancer.(5,9,14) A
survey of multiple myeloma patients revealed that 40% had
vitamin D deficiency (36 nmol/L) and 35% had vitamin D
insufficiency (36 to 75 nmol/L).(15) Vitamin D insufficiency
(< 50 nmol/L) was reported for 30.2% of breast cancer
patients.(16) Although the vitamin D status of ONJ patients has
not been established,(17,18) the high-risk populations for ONJ
appear to overlap with those with inadequate vitamin D levels.
The implication of a role for vitamin D in ONJ is further seen in a
prospective clinical study reporting that patients who exhibited
significantly elevated serum levels of immunoreactive parathyr-
oid hormone (iPTH) (likely owing to vitamin D insufficiency)
prior to and throughout BP treatment eventually developed
ONJ. Conversely, patients with normal iPTH levels prior to BP
treatment did not develop ONJ.(17)
The objective of this study was to develop a rat model of ONJ
that would consistently present lesions that are equivalent those
seen in human disease. Because the pathologic mechanism of
ONJ is virtually unknown, this study examined combinations of
risk factors: BP intravenous injection, tooth extraction, and
predisposing vitamin D deficiency. It was found that ONJ lesions
developed most frequently in rats with all three risk factors.
Materials and Methods
Histopathologic characterization of human ONJ biopsy
specimens
From the pathology archive of UCLA School of Dentistry from
2006 to 2007, 10 eligible microscopic slides were identified using
the following criteria: confirmed clinical diagnosis of ONJ and
recorded use of BP. The degree of histologic osteonecrosis was
determined from the percent of empty osteocytic lacunae and
pycnotic nuclei of osteocytes to the total number of osteocytes.
In some cases, Actinomyces infection was evaluated by modified
Grocott’s methenamine silver (GMS) staining. This study was
approved by the UCLA Institutional Review Board.
Vitamin D–deficient rat model
In order to induce vitamin D deficiency [VitD()], 6- to 8-week-old
Sprague-Dawley rats (Charles River Laboratories, Inc., Wilmington,
MA, USA) were fed a diet lacking vitamin D (TD.89123: 0.47%
calcium, 0.3% phosphorus; Harlan Teklad, Madison, WI, USA) and1338 Journal of Bone and Mineral Researchhoused under a 12-h light/dark cycle. Ultraviolet B (UVB)
emission (290 to 305 nm) in the action spectrum for cutaneous
vitamin D synthesis was not detected from the fluorescent light
fixtures in the animal housing. Vitamin D–sufficient rats were
fed a normal rodent diet (TD.7013: 1.19% calcium, 0.92% phos-
phorus, 4.21 IU/g vitamin D3; Harlan Teklad, Madison, WI, USA)
and kept in the same housing. Postfasting periphery blood
was collected after 3 weeks. The serum samples were used to
measure 25-hydroxyvitamin D3 [25(OH)D] and rat-specific
immunoractive PTH (iPTH) by radioimmuno assays (Anilytics,
Inc., Gaithersburg, MD, USA). The serum levels of calcium (Ca),
phosphorous (P), alkaline phosphatase (ALP), and magnesium
(Mg) were measured using a conventional method. C-terminal
cross-linking telopeptide of type I collagen (CTX) and serum
band 5 of tartrate-resistant acid phosphatase (TRACP-5b) were
measured by enzyme-linked immunosorbent assays (RatLaps
ELISA, Nordic Bioscience Diagnostics, Herlev, Denmark; RatTRAP
Assay, IDS, Inc., Fountain Hills, AZ, USA, respectively). The data
were analyzed using Student’s t tests, and statistical significance
was accepted for p< .05. All animal experiments were approved
by the UCLA Animal Research Committee.
BP intravenous injection
The ZOL and VitD()/ZOL groups were produced by treating
VitD(þ) and VitD() rats with an intravenous injection of a bolus
of zoledronate (Zometa, Novartis, Basel, Switzerland; 35mg/kg in
0.9% NaCl) through a tail vein. The remaining rats, each in the
control and VitD() groups, received an intravenous injection of
vehicle solution (0.9% NaCl). The intravenous injection was
repeated every 2 weeks (Fig. 1A). The human protocol for ZOL is
4mg per infusion in intervals of every 3 to 4 weeks.(19) Given an
average human body weight of 55 to 60 kg, the dose was
determined as 70mg/kg every 4 weeks. Because the excretion
rate of injected ZOL in rats has not been established, we
employed more frequent ZOL injections, 35mg/kg ZOL every
2 weeks, but maintained the cumulative dose to be equivalent to
the human dose of 70mg/kg for the 4-week period.
Tooth extraction
Maxillary left molar teeth were extracted from all groups at
3 weeks after initiating the systemic treatment using previously
established methods.(20) Briefly, rats were anesthetized through
inhalation of 2% isoflurane and placed in the supine position on
a custom operation table. A dental explorer was used to separate
the gingival attachment and to gently luxate the tooth. Sub-
cutaneous injections of 0.05mg/kg buprenorphine were given
every 12 hours for 48 hours after tooth extraction, but no
antibiotics were given.
Identification of ONJ lesion and the prevalence of
ONJ in rats
Then 1, 2, 4, and 8 weeks after tooth extraction, maxillae were
harvested from the control, VitD(), ZOL, and VitD()/ZOL
groups. The tissue specimens were immediately fixed in 10%
buffered formalin and photographed. The fixed tissue specimens
were first examined by micro-computed tomography (mCT40,
Scanco Medical, Bassersdorf, Switzerland) at an X-ray energyHOKUGO ET AL.
Fig. 1. Rat ONJ model. (A) The treatment sequence to generate the confluence of factors: vitamin D deficiency [VitD()]; the serial intravenous injections
of nitrogen-containing BP [zoledronate (ZOL)] and extraction of maxillary molar teeth. (B) Serum chemistry at the time of tooth extraction demonstrated
the establishment of vitamin D deficiency. (C) Rat maxilla with tooth extraction wound healing (right) and untreated molars (left) harvested 2 weeks after
tooth extraction. The VitD()/ZOL group exhibited delayed wound healing with the alveolar bone exposure (arrow). (D) Reconstructed mCT image of the
rat maxilla 4 weeks after tooth extraction. The tooth extraction socket was nearly filled with newly formed bone. The wound healing of the VitD()/ZOL
group appeared to be delayed, and detached bone sequestra of various sizes (white arrows) were observed.level of 55 kVp with a current of 72mA. A 3D image of the maxilla
was constructed using a customized computational program.
The tissue specimens then were decalcified with 10% ethy-
lenediaminetetraacetic acid (EDTA) and processed for paraffin
embedding. A series of 4-mm-thick sections in the frontal plane
were prepared through the second to third molars of the intact
side as the reference and in the same area around the extraction
site. The number of total osteocyte lacunae and the number
of empty osteocytic lacunae or pycnotic nuclei of osteocytes
were counted within the buccual alveolar bone of the second
molar for both the intact side and the contralateral (tooth
extraction) side. In each section, the measurement was
performed in five nonoverlapped fields under 40 magnifica-
tion. In the same specimen, when bone sequestra were
observed, the number of total osteocyte lacunae and the
number of empty osteocytic lacunae or pycnotic nuclei ofBISPHOSPHONATE-RELATED ONJ IN VITAMIN D–DEFICIENT RATSosteocytes were counted separately. The ratio of nonvital
osteocytes to the total osteocytes was calculated. Histologic
bone exposure was determined by observation of direct
communication to the oral cavity or oral epithelial tissue in
approximation to the bone. The presence of Actinomyces
infection was examined by GMS staining. The ONJ lesion was
defined as alveolar bone or bone sequestrum containing areas of
nonvital osteocytes with histologic bone exposure to the oral
cavity.
The prevalence of ONJ was determined from specimens at
4 weeks after tooth extraction and was defined as the number
of animals positive for histologic ONJ lesion(s) divided by the
total number in the group and expressed as a percent. The
statistical significance of ONJ prevalence between the experi-
mental groups was determined by Fisher’s exact test,(21) and
statistical significance was accepted for p< .05.Journal of Bone and Mineral Research 1339
Serum chemistry and femur mCT bone morphometry
Peripheral whole-blood samples were collected 4 weeks after
tooth extraction from the control, VitD(), ZOL, and VitD()/ZOL
groups (Fig. 1A), and serum chemistry was examined as
disscussed earlier. Serum chemistry for each group was analyzed
using one-way ANOVA followed by Dunnet’s test, and statistical
significance was accepted for p< .05.
Femur bones also were harvested and fixed in 10% buffered
formalin and subjected to mCT scanning (m-CT40, Scanco Medi-
cal, Bassersdorf, Switzerland) at an X-ray energy level of 55 kVp, a
current at 72mA, and an isotropic resolution of 16mm. One-
hundred and fifty slices (3.0mm) were evaluated in the distal
femur metaphysis at a threshold of 250.(22) The volume of
interest included only secondary spongiosa. Trabecular bone
morphometric measurements in 3D included bone volume nor-
malized to tissue volume (BV/TV), trabecular structure con-
nectivity density (Conn.D), trabecular number (Tb.N), trabecular
thickness (Tb.Th), and trabecular separation (Tb.Sp). The data
were evaluated by Dunnet’s test, and statistical significance was
accepted for p< .05.
Characterization of osteoclasts in the maxillary alveolar
bone
Histologic specimens of the maxilla surrounding the tooth
extraction site at 4 weeks after tooth extraction were stained in
situ for tartrate-resistant acid phosphatase (TRACP) using a
commercially available kit following the manufacturer’s protocol
(Sigma, St. Louis, MO, USA). The number of osteoclasts defined
by TRACPþ multinuclear cells (3 nuclei) was counted on the
external surface of post–tooth extraction alveolar bone. Adjacent
histologic sections were stained with in situ terminal deox-
ynucleotidyl transferase–mediated deoxyuridine triphosphate–
biotin nick-end label (TUNEL) using a commercially available
kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan, and
Calbiochem, San Diego, CA, USA). The number of TUNELþ
multinuclear cells (3 nuclei) on the external surface of post–
tooth extraction alveolar bone was counted. The data were
evaluated by Dunnet’s test, and statistical significance was
accepted for p< .05.
Micro-positron emission tomography (mPET)
Four weeks after tooth extraction, static mPET images were
obtained, using [18F]fluorodeoxyglucose (FGD) or [18F]fluoride
ions freshly prepared by an RDS cyclotron (Siemens Preclinical
Solutions, Munich, Germany). Rats (n¼ 4 in each group) were
injected with 74 MBq of [18F]FDG or [18F]fluoride ion tracers via
the tail vein andmaintained under gas anesthesia for 1 hour, and
then head scans were performed with a 10-minute acquisition
time usingmPET (FOCUS 220 system, CTI ConcordeMicrosystems
LLC, Knoxville, TN, USA). Immediately afterward, non-contrast-
enhanced mCT scans were obtained (mCAT II, Siemens Preclinical
Solutions) with a 10-minute acquisition time. PET scan images
were reconstructed using filtered backprojection and an iterative
3D maximum a posteriori (MAP) reconstruction technique.(23)
Filtered backprojection images were used for quantification of
tracer uptake by AMedical Image Data Examiner (AMIDE, Version1340 Journal of Bone and Mineral Research0.7.15, Geeknet, Inc., Mountain View, CA). Plain anteroposterior
radiographs were superimposed on reconstructed PET images,
and tooth extraction socket sites were identified and marked for
each scan. Regions of interest (ROIs) in a box configuration
measuring 2 5mm then were drawn on horizontal images
encompassing the extraction site. ROIs were applied to several
successive planes measuring 3mm in depth. The size of the ROI
was standardized to approximate the actual size of the extraction
wound. ROIs of identical size a were lso set at the contralateral
nonextraction site as a control. Mean signal intensity (MBq/cc)
within the volumes of interest was calculated using the AMIDE
data-analysis tool. Values then were corrected for rat weight and
actual tracer dose injected. Data were reported as standardized
uptake value (SUV) and evaluated by two blinded reviewers. The
percent of SUV was calculated to allow relative comparisons
between the extracted and nonextracted sites. The data were
analyzed by Dunnet’s test, and statistical significance was
accepted for p< .05.
Expression of immune/inflammation-related genes
Total RNA samples were prepared from maxillary oral mucosa
tissues overlying the week 4 tooth extraction site using a com-
mercially available kit (Qiagen, Valencia, CA, USA). A quantitative
real-time polymerase chain reaction (RT-PCR)–based array
system (Rat Th1–Th2–Th3, PARN-034, SABioscience, Frederick,
MD, USA)was used for assessing the expression profile of immune/
inflammation-related genes. This array contained 84 spotted
cytokine gene probes representative of helper T cells. In addition,
RT-PCR of C—C motif chemokine 3 (CCL3; Rn00564660_m1,
Applied Biosystems, Foster City, CA, USA) was performed. Total
RNA from gingiva tissue harvested from intact maxilla of the
control group was used as reference control.
Results
Human ONJ lesions
In the human ONJ biopsy specimens, the percentages of nonvital
osteocytic lacunae were found to range from 66% to 100%,
with an average 93% 12% (Table 1). GMS staining revealed
Actinomyces colonies in bone marrow spaces or on the surface of
sequestrum in 90% of specimens (Table 1). In 6 of 10 specimens,
nonkeratinized epithelial tissue ingrowth into the lesions, so-
called pseudoepitheliomatous hyperplasia (PEH), was observed
adjacent to the bone sequestrum (Table 1).
Establishment of vitamin D deficiency in rats
Rats fed a vitamin D–deficient diet for 3 weeks exhibited vitamin
D deficiency. This was demonstrated by significant decrease in
serum 25(OH)D compared with vitamin D–sufficient control
animals (Fig. 1B). Serum calcium, phosphorus, and magnesium
levels were not affected. In addition, iPTH CTX and TRACP-5b
levels of the VitD() group were significantly increased over
those of the control group. These results confirm the expected
presence of secondary hyperparathyroidism and increased bone
turnover in VitD() rats.HOKUGO ET AL.
Table 1. Histopathologic Evaluation of Human ONJ Biopsy
Specimens
Parameter
Subject
no.
Actinomyces
infection
Pseudoepitheliomatous
hyperplasia (PEH)
Empty
osteocyte
lacunae (%)
1 þ þ 100.0
2 þ þ 79.1
3 þ þ 100.0
4 þ þ 66.0
5 þ þ 100.0
6 þ  100.0
7 þ þ 84.1
8 þ  97.7
9   100.0
10 þ  100.0
Summary 90% 60% 92.70 12.08Compromised tooth extraction wounding in the VitD()/
ZOL group
Two weeks after unilateral maxillary molar extraction, the open
wound of maxillary oral mucosa generally closed over the
extraction site in the control, VitD(), and ZOL groups. However,
the VitD()/ZOL group showed delayed healing with alveolar
bone exposure (Fig. 1C). The 3D reconstructed mCT images of the
maxilla specimens 4 weeks after tooth extraction revealed that
the extraction socket was filled with healing bone in the control,
VitD(), and ZOL groups. In contrast, the VitD()/ZOL group
showed delayed and irregular wound healing and a number of
bone fragments detached from the alveolar bone (white arrows
in Fig. 1D). In all groups, no gross abnormalities were observed
on the nonextraction side of maxilla with intact molar teeth and
gingiva.
Two weeks after tooth extraction, the maxillary wound site of
the VitD()/ZOL group revealed an area of nonvital alveolar
bone (Fig. 2A). The wound edge of oral mucosa continued to be
patent, and epithelial cells extended along the surface of
necrotic bone. Along the deep margin of alveolar bone, there
was immature bone with numerous cement lines associated with
a diffuse, mild, inflammatory infiltrate. Four weeks after tooth
extraction, partially necrotic bone fragments or sequestra (sq in
Fig. 2B, Table 2) were observed, which were surrounded by
inflammatory granulation tissue and were positive for Actino-
myces infection (Fig. 2C). Although the wound edge of oral
mucosa appeared to close, nonkeratinized oral epithelium
grew toward the sequestrum, a lesion consistent with PEH
(Fig. 2B, D). Necrotic bone sequestra with PEH seemed to persist
in the VitD()/ZOL group even 8 weeks after tooth extraction
(Fig. 2D). The oral exposure of bone sequestrum appeared to be
established by PEH-mediated fistulation.
In the control group, the tooth extraction wound showed
active osteoclasts within resorption lacunae and lining osteo-
blastic cells compatible with repair of the maxillary defect
(Fig. 2D, Cont). There were sporadic small epithelial inclusionsBISPHOSPHONATE-RELATED ONJ IN VITAMIN D–DEFICIENT RATSsurrounded by multinucleated giant cells (foreign-body type).
Compared with the control group, the tooth extraction wound in
the VitD() group was filled with more immature bone that
contained numerous cement lines and osteoclasts and demon-
strated extension of the hematopoietic marrow space to near the
bone surface (Fig. 2D, VitD()). In the ZOL group, new bone in
the extraction socket displayed prominent cement lines (Fig. 2D,
ZOL). The intervening stroma was cellular and contained scatt-
ered inflammatory cells.
The ONJ prevalence in rats
The histologic specimens taken 4 weeks after tooth extraction
from each group were selected for the prevalence study. The
ratio of nonvital osteocytes (necrotic bone area) was significantly
greater in the buccal alveolar bone of the tooth extraction
side than in the unwounded side (p< .05) in the VitD()/ZOL
group. The necrotic bone area in the tooth extraction side was
greater in the VitD()/ZOL group than in the control group
(p< .05; Table 2). Bone sequestra were observed in all groups,
although the number was highest in the VitD()/ZOL group. The
size of bone sequestrum measured by the total number of
osteocyte lacunae was found to be significantly larger in the ZOL
group than in the other groups (Table 2). Bone sequestra of the
ZOL group maintained the characteristic structure of alveolar
bone, suggesting that traumatic bone fracture during tooth
extraction might have occurred in some animals in the ZOL
group. On the contrary, bone sequestra in the VitD() and
VitD()/ZOL groups appeared to be subjected to extensive
osteoclastic activity. Dense localized inflammatory cell infiltrates
were associated with bone sequestra in the VitD()/ZOL group.
However, inflammation was noticeably less severe in the VitD()
group, in which bone sequestra were surrounded by granulation
tissue (Fig. 2D).
Bone exposure to the oral cavity was observed most fre-
quently in the tooth extraction side of the VitD()/ZOL group
(Table 2). None of the unwounded side specimens indicated oral
bone exposure. ONJ lesions were most prevalent in the VitD()/
ZOL group (66.7%; four positive rats of six total rats), followed by
the ZOL group (14.3%; one of seven). None of animals in the
control (n¼ 9) and VitD() (n¼ 7) groups developed ONJ lesions.
The Fisher exact test indicated that ONJ prevalence in the
VitD()/ZOL group was significantly greater than in all other
groups (p< .05; Fig. 2F).
The effect of ZOL in serum chemistry and femur bone
morphometry
The serum chemistry data (4 weeks after the tooth extraction)
indicated vitamin D deficiency accompanied by hyperparathyr-
oidism and hypocalcaemia in the VitD() and VitD()/ZOL
groups (Table 3). The CTX level was elevated in the VitD()
group, which was attenuated by ZOL treatment. The TRACP-5b
level was decreased in the VitD()/ZOL group compared with
the control and VitD() groups (Table 3).
mCT bone morphometry of the femur metaphysis depicted
osteopenic bone structure in the VitD() group, highlighted by
decreased Tb.N and increased Tb.Sp. ZOL treatment not onlyJournal of Bone and Mineral Research 1341
Fig. 2. Histologic rat ONJ lesion. (A) In the VitD()/ZOL group, frontal sections through the second to third molars of rat maxilla 2 weeks after tooth
extraction depicted partially necrotic alveolar bone (arrow) exposed to the oral cavity () through patent oral mucosa. Bar¼ 100mm. (B) Detached necrotic
bone sequestrum (sq) associated with pseudoepitheliomatous hyperplasia (PEH; small arrows) in a VitD()/ZOL rat. Bar¼ 100mm. (C) Necrotic bone
sequestrum in panel B stained with modified GMS indicated the presence of Actinomyces. Bar¼ 100mm. (D) In the control, VitD(), and ZOL groups, the
tooth extraction socket was healed 4 weeks after tooth extraction. The sign of osteonecrosis was not observed. However, the necrotic bone sequestra (sq)
sustained the oral exposure through PEH (small arrows) 4 and 8weeks after tooth extraction in the VitD()/ZOL group. Bar¼ 200mm. ( F) The prevalence of
rats exhibiting the osteonecrosis lesion defined as partial osteonecrosis with 60% or more empty osteocyte lacunae exposed to the oral cavity. (G) The
prevalence in each group was compared by Fisher’s exact test.
Table 2. Characterization of Maxillary Alveolar Bone Osteonecrosis
Treatment
Parameter Control VitD() ZOL VitD()/ZOL
Empty osteocyte lacunae of Unwounded side 6.7 1.5 6.2 2.1 7.3 3.2 7.4 1.3
buccal alveolar bone (%) Tooth ext. side 7.2 1.2 6.9 2.5 9.2 4.9 11.3 1.4 ,
Occurrence of bone exposure (%) Unwounded side 0 0 0 0
Tooth ext. side 0 0 14.3 66.7,
Number of bone sequestra after tooth extraction 0.3 0.7 1.3 1.8 0.9 0.9 1.3 1.5
Size of bone sequestrum (total osteocyte lacunae) 24.7 24.5 50.1 27.4 93.8 16.8 31.9 22.0
Empty osteocyte lacunae/bone sequestrum (%) 54.8 30.6 84.6 14.2 83.7 11.8 83.4 14.3
p< .5 versus control.
p< .5 versus unwounded side.
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Table 3. Serum Chemistry Measurements 4 Weeks After Tooth Extraction
Parameter
Treatment 25(OH)D (ng/mL) PTH (pg/mL) Ca (mg/dL) P (mg/dL) ALP (U/L) CTX (ng/mL) TRACP-5b (U/L)
Control 16.14 2.91 50.6 7.2 11.23 0.17 9.63 1.20 172.7 21.7 36.04 4.97 5.10 0.81
VitD() 0.44 0.06 448.3 27.2 9.34 0.74 9.70 0.31 270.2 20.9 63.85 5.93 5.10 1.29
ZOL 17.45 1.63 234.0 62.2 10.42 0.18 8.14 0.25 212.4 21.0 27.76 3.54 2.43 0.32
VitD()/ZOL 0.62 0.10 649.2 131.4 7.46 0.89 9.62 0.45 276.8 52.5 34.44 3.46 1.58 0.16,
p< .05 versus control.
p< .05 versus VitD().reversed the VitD()-induced trabecular bone loss but further
increased the bone structural indices (Table 4).
Increased osteoclastogenesis and osteoclast apoptosis in
the post–tooth extraction oral bone of the VitD()/ZOL
group
The average number of osteoclasts (TRACPþ multinuclear cells)
located on the external surface of post–tooth extraction alveolar
bone (Fig. 3A) was significantly increased in the VitD() and
VitD()/ZOL group compared with the control and ZOL groups
(Fig. 3B). Following TUNEL staining, a larger number of TUNELþ
osteoclasts was observed in the VitD()/ZOL group compared
with all other groups (Fig. 3C).
Sustained inflammation in the post–tooth extraction oral
bone of the VitD()/ZOL group
The metabolic activity of maxillary alveolar bone was evaluated
by mPET. The standardized uptake value (SUV) of [18F]FGD for
maxillary alveolar bone of the nonextraction side was evaluated
initially by the two-way ANOVA, which indicated no significant
difference among all groups (Fig. 3D). The normalized [18F]FGD
SUV of the tooth extraction side was significantly higher in the
VitD()/ZOL group than in the control group (Fig. 3E). The
normalized [18F]FGD SUV of the tooth extraction side of the
VitD() and ZOL groups did not differ significantly from control
(data not shown). On the contrary, the normalized SUV of
[18F]fluoride ion of the tooth extraction side decreased
significantly in the VitD()/ZOL group compared with the
control group (Fig. 3F), whereas other groups did not show any
differences (data not shown).
In the VitD()/ZOL group, the localized inflammatory cell
aggregation was observed adjacent to the bone surface, whichTable 4. Effect of VitD() and ZOL on Trabecular Bone Architecture
Treatment BV/TV (%) Conn.D. (mm3) T
Control 18.70 3.38 53.84 11.92 2
Vit D() 7.46 2.19 26.53 10.80 1
ZOL 57.92 8.37, 163.95 21.54 7
VitD()/ZOL 41.54 16.09, 170.32 26.37, 6
p< .05 versus control.
p< .05 versus VitD().
BISPHOSPHONATE-RELATED ONJ IN VITAMIN D–DEFICIENT RATSwas not seen in other groups (Fig. 3G). The densely localized
inflammatory cells were composed primarily of neutrophils and
lymphocytes. Uniquely, these inflammatory cells were found to
juxtapose osteoclasts with pycnotic nuclei (Fig. 3G, H). There
were no significant inflammatory cell infiltrates within the bone
marrow space.
Expression of immune/inflammation-related genes
The expression profile of Th1, Th2, and Th3 cytokine gene
products was characterized in our model. Because apoptotic
osteoclasts and accumulation of inflammatory cells were largely
observed on the external surface of alveolar bone after tooth
extraction, oral mucosa tissue overlying alveolar bone was
selected for this experiment. Compared with the control group,
the gene expression profile of the VitD() group was not
significantly altered (Fig. 4A). The ZOL treatment groups showed
elevated CCL3, IL6, and IL6. SPP1 was found decreased in
the VitD() and VitD()/ZOL groups, although statistical signi-
ficance was reached only in the VitD()/ZOL group. Compared
with the ZOL group, the VitD()/ZOL group had a clear tendency
in elevated expression of Th1 cytokines such as tumor necrosis
factor a (TNF-a) and interleukin 12b (IL-12b) (p< 0.05), as well
as interferon-g (IFN-g) (p¼ 0.07). In contrast, Th2-related genes
such as IL10 and CD27 were found to be downregulated in the
VitD()/ZOL group (Fig. 4B).
Discussion
Establishment of a rat ONJ model
This study demonstrated the development of ONJ lesions after
tooth extraction in vitamin D–deficient rats treated with ZOL
intravenous injections. Histologic characteristics of the rat ONJas Assessed by mCT of the Femur Distal Metaphysis
Parameter
b.N (mm1) Tb.Th (mm) Tb.Sp (mm)
.89 0.82 86.00 0.79 369.37 119.99
.02 0.23 71.13 3.56 1060.30 268.73
.50 0.38, 129.00 15.32, 115.78 23.54
.39 1.17, 97.78 23.43 154.05 46.26
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Fig. 3. Characterization of the rat ONJ lesion. (A) A cluster of TRACPþ multinuclear cells at the external surface of alveolar bone at 4 weeks after tooth
extraction in a VitD() rat. Bar¼ 50mm. (B) The number of TRACPþ multinuclear cells (n¼ 4 in each group; p< .05 versus control). (C) The number of
TUNELþmultinuclear cells found for alveolar bone 4 weeks after tooth extraction (n¼ 4 in each group; p< .05 versus control). (D) Superimposed images of
mPETwith [18F]FDG andmCT. SUV of the tooth extraction site (arrows) was normalized, with the opposite side alveolar bone containing the remaining teeth
(arrowheads) in the same animal. (E) The [18F]FDG SUV in the tooth extraction site normalized by the unwounded side (

p< .05 versus control). ( F) The
[18F]fluoride SUV in the tooth extraction site normalized by the unwounded side (

p< .05 versus control). (G) The surrounding oral mucosal tissue of post–
tooth extraction alveolar bone of control and VitD()/ZOL rats. Osteoclasts (arrows) were found on the external surface. In the VitD()/ZOL group, a dense
cluster of inflammatory cells (arrowheads) was found juxtaposed on the necrotic bone surface. (H) Osteoclasts (arrows) undergoing apoptosis of post–
tooth extraction alveolar bone in the VitD()/ZOL group were associated with a cluster of inflammatory cells composed of neutrophils and lymphocytes.lesion appeared to closely resemble the human disease. Human
ONJ lesions have been shown to consist of multiple, partially
confluent areas of necrotic bone containing residual nests of vital
bone and were distinct from osteoradionecrosis lesions having
extended homogeneous regions of complete bone necrosis.(24)
The rat ONJ lesion similarly exhibited partially necrotic areas
(Fig. 2A, D). The hallmark of confirmed ONJ is the prolong1344 Journal of Bone and Mineral Researchexposure of necrotic bone to the oral cavity.(10,25,26) Healing of
the tooth extraction wound was delayed in the VitD()/ZOL
group, where the oral wound did not close for at least 2 weeks.
All other groups showed uneventful oral mucosa wound closure
by gross observation(27,28) (Fig. 1C). Histologically, the exposure
of necrotic bone to the oral cavity persisted at 4 and 8 weeks
after tooth extraction in the VitD()/ZOL group. This exposureHOKUGO ET AL.
Fig. 4. RT-PCR-based microarray assay depicted immune/inflammation-related gene expression. (A) The expression of CCL3, IL6, and SPP1 in the oral
mucosal tissues harvested from 4-week post–tooth extraction maxillae was affected by ZOL treatments but not by vitamin D deficiency alone. (B). In the
ZOL-treated groups, vitamin D deficiency appeared to increase the expression of Th1-related genes (TNFa, IL12b, and IFNg) and blunt the Th2-related
genes (IL10 and CD27) compared with the ZOL group.

p< .05 versus the control group; yp< .05 versus the ZOL group.was indicated by food particles trapped between PEH and bone
sequestrum (Fig. 2D). PEH was described originally as a skin
disease with an exuberant proliferation of epidermal tissue(29)
and has been reported as a rare complication of fistulated
chronic osteomyelitis distinct from neoplastic lesions in the
jawbone.(30) Akilov and colleagues (2007) demonstrated in the
experimental cutaneous leishmaniasis mouse model that intra-
lesional injections of TNF-a and IFN-g initiated PEH in mouse ear
skin.(31) The upregulation of TNF-a and IFN-g in postextraction
oral mucosa of the VitD()/ZOL group (Fig. 4) appears to provide
a pathologic mechanism to develop PEH in our model. PEH was
found in approximately 60% of human ONJ biopsy specimens(24)
(Table 1). It must be noted that the unwounded side of alveolar
bone did not show any sign of ONJ, suggesting that tooth
extraction was a significant risk factor for developing ONJ in
rats. From these findings, we propose that the persistent oral
exposure of bone in ONJ may be mediated in part by PEH, which
likely is induced by upregulated T-helper type 1 (Th1) cytokines
associated with oral wounding (Fig. 5).
The effect of ZOL
Our study reports the development of ONJ lesions in vitamin D–
deficient rats receiving one or two human-equivalent parenteral
doses. In this study, rats received two intravenous ZOL injections
at the time of molar extraction (a cumulative total dose of 70mg/
kg) and received four injections (a cumulative total dose of
140mg/kg) at 4 weeks after tooth extraction. However, theBISPHOSPHONATE-RELATED ONJ IN VITAMIN D–DEFICIENT RATSexperimental dose of ZOL for rodents varies among reports.
Croucher and colleagues (2003) used 120mg/kg subcutaneous
ZOL injections twice a week in a multiple myelomamouse model
(a cumulative dose of 240mg/kg per week and 960mg/kg for
4 weeks at the termination point).(32) Gasser and colleagues
(2008) investigated the effectiveness of ZOL in a single intra-
venous injection in ovariectomized (OVX) rats with doses ranging
from 0.8 to 500mg/kg.(33) The attenuation of total bone mineral
density (BMD) loss was found with as little as a single injection
of 4mg/kg of ZOL, and the effect of an injection of 20mg/kg
of ZOL was found to be equivalent to that of an injection of
200mg/kg of alendronate. Treatment of female OVX rats(33,34) or
male orchidectomized (ORX) rats(35) with various BPs showed
the attenuation of bone morphometric measurements and
decreased serum CTX or TRACP-5b values compared with unt-
reated OVX or ORX rats. This study showed the effect of ZOL
treatment on improvement of trabecular bone structure (Table 4).
The elevated CTX values from VitD() treatment also were atten-
uated by ZOL treatment (Table 3). These data suggest that our
experimental protocol generated the expected anticatabolic effect
in bone.
BPs are known to be stable compounds and may be acc-
umulated in skeletal tissues after repeated administration. It
must be noted that BP treatment alone did not increase the
prevalence of ONJ (Fig. 2), although the effect of long-term BP
treatment was not addressed in our study. It may be possible that
different doses as well as injection protocols could affect the
prevalence and/or severity of ONJ. Further studies are needed.Journal of Bone and Mineral Research 1345
Fig. 5. Hypothetical pathophysiologic mechanism of ONJ, in which the interaction between BP treatment and vitamin D deficiency may induce
dysregulation of bone homeostasis and innate immunity.Apoptotic osteoclasts in the post–tooth extraction
alveolar bone of the VitD()/ZOL group
Tooth extraction induces transient and localized osteoclasto-
genesis on the external surface of alveolar bone, which normally
returns to the baseline level 4 weeks after tooth extraction in
rats.(36) A novel observation in this study was that vitamin D
deficiency appeared to sustain osteoclastogenesis even 4 weeks
after tooth extraction (Fig. 3A). Anderson and colleagues (2009)
reported the development of osteopenia in vitamin D–deficient
rats associated with the increased osteoclast surface (Oc.S) in
femurs and vertebral bones.(37) The increased ratio of steady-
state mRNA levels of RANKL over osteoprotegerin (OPG) in femur
bone marrow of vitamin D–deficient rats has been postulated to
be responsible for the increased osteoclastogenesis.(37) In our
study, the introduced vitamin D deficiency similarly may con-
tribute to the increased osteoclastogenesis during tooth ext-
raction wound healing.
TUNEL staining was found to be positive in approximately 10%
of multinuclear cells in alveolar bone of the control and VitD()
groups, whereas nearly 50% of osteoclasts in the ZOL and
VitD()/ZOL groups appeared to become TUNELþ. As a result, a
large number of osteoclasts underwent apoptosis in the VitD()/
ZOL group (Fig. 3C). The combination of vitamin D deficiency and
ZOL treatment may cause this extensive osteoclast apoptosis in
the oral cavity.
Decreased bone-formation activity of post–tooth
extraction alveolar bone in the VitD()/ZOL group
mPET with [18F]fluoride ion depicts the de novo bone-formation
activity. The noticeable decrease in uptake of [18F]fluoride ion to
the tooth extraction wound of the maxilla of the VitD()/ZOL
group may be due to the decreased bone turnover rate of1346 Journal of Bone and Mineral Researchjawbones (Fig. 3D). Vitamin D deficiency induced secondary
hyperparathyroidism in rats (Fig. 1B and Table 3). Since osteo-
dystrophy symptoms after renal failure have been linked to
hyperparathyroidism,(38) the elevated PTH may have contributed
to the decreased bone remodeling in the VitD()/ZOL group.
However, because mPET with [18F]fluoride ion uptake was not
modulated in the VitD() group with high PTH levels, its
significance in the ONJ pathogenesis could not be determined in
this study.
Osteomyelitis-like inflammation and ONJ
mPET evaluations revealed that there was increased [18F]FDG
tracer accumulation in the VitD()/ZOL group (Fig. 3E), indicat-
ing significant inflammation at the post–tooth extraction
alveolar bone, similar to reports of human ONJ cases.(39)
Wounding by tooth extraction induces transient inflammatory
reactions, which generally subside by week 4 in rats.(40,41) The
VitD()/ZOL group showed dense localized accumulation of
inflammatory cells adjacent to necrotic bone composed largely
of neutrophils and lymphocytes (Fig. 3G, H). Both [18F]FDG mPET
and histologic features were thought to be consistent with
osteomyelitis,(42) inflammation of bone and bone marrow owing
to a pyogenic infection. In this study, rat ONJ lesions exhibited
Actinomyces infection of a limited scope (Fig. 2C). Furthermore,
the persistent communication to the oral cavity through PEH
may make the bone sequestra in the VitD()/ZOL group
susceptible to infection. Recently, the microbial-activated
toll-like receptors have been shown to upregulate the expression
of vitamin D receptors (VDRs) and CYP27b1-hydroxylase in
human macrophages.(43) The human cathelicidin antimicrobial
peptide gene is a direct transcriptional target of VDR-1,25
(OH)2D interaction in those cells.
(43,44) Therefore, an insufficientHOKUGO ET AL.
25(OH)D level a may lso result in prolongation of bacterial
infection of the mouth.
Dysregulation of oral innate immunity as a potential
pathophysiologic mechanism of ONJ
A unique histopathologic feature in the VitD()/ZOL group was
that the dense inflammatory cell infiltration associated with the
surface of partially necrotic bone, where a cluster of inflamma-
tory cells was found juxtaposing apoptotic osteoclasts (Fig. 3G,
H). This unique osteomyelitis-like inflammatory reaction may
not be due only to bacterial infection. Nitrogen-containing BPs,
once incorporated in the cell, interfere with the mevalonate
biosynthetic pathway, in which BPs have been shown to com-
pete with isopentenyl diphosphosphate (IPP) as a substrate
of farnesyl diphosphate synthase (FPPS). As a result, IPP is
abnormally accumulated, whereas downstream events of
FPPS such as prenylation of small GTPase proteins are effectively
prevented, and this leads to cell death.(47,48) It has been
documented that the release of IPP from BP-treated monocytes
serves as the putative ligand for T cells carrying gd T cell
receptor.(49) Although gd T cells represent a small population of
peripheral blood lymphocytes (1% to 5%), they can infiltrate into
epithelial tissues, including oral mucosa.(50,51) It may be theorized
that the excessive number of osteoclasts undergoing apoptosis
in BP-treated groups could result in the release of IPP to the
immediate field, above the critical level for activating gd T cells in
the oral mucosa. Because 1,25(OH)2D has been shown to inhibit
phospholigand-induced gd T cell expansion,(52) IPP-induced gd
T cells may further activated in the vitamin D–deficient
environment. The IPP-induced gd T cells have been shown to
secrete the chemokine CCL3 (MIP-1a), a potent chemoattractant
for neutrophil migration, at the equivalent level to those induced
by bacterial lipopolysaccharides.(53,54) In this study, a significantly
elevated CCL3 expression was found in the oral mucosa tissue of
the ZOL and VitD()/ZOL groups (Fig. 4A), which may support
the postulated role of BP-induced osteoclast apoptosis in the
localized inflammatory reaction.
In contrast, Th1 cytokine expression pattern was different
between the ZOL and VitD()/ZOL groups. Compared with the
ZOL group, the VitD()/ZOL group had a clear tendency toward
elevated expression of Th1 cytokines (Fig. 4B). Activated VDR-
and CYP27B1 hydroxylase–expressing macrophages produce
1,25(OH)2D.
(45) Acting through its receptor, 1,25(OH)2D is known
to promote the innate immune response and limit the Th1
response in the local inflammatory microenvironment.(46) Our
underlying hypothesis holds that diminished 1,25(OH)2D production
in the oral mucosa in the presence of relatively low substrate
25(OH)D levels will impede the normal innate and adaptive
immune reaction in response to massive BP-driven apoptosis of
osteoclasts at the extraction site. Hence, in the absence of locally
produced 1,25(OH)2D owing to diminished availability of
substrate 25(OH)D, the Th1 response is amplified and the Th2
response is blunted. This was the case in the persistent wounds
present in the vitamin D–deficient ZOL-treated rats reported
here (Fig. 4B).
We did not observe a similar cytokine response from VitD()
animals at 4 weeks after tooth extraction. We propose that thisBISPHOSPHONATE-RELATED ONJ IN VITAMIN D–DEFICIENT RATSwas the consequence of successful wound healing in that group
in the absence of coadministered BP. We postulate that the
interaction between BP treatment and vitamin D deficiency
may generate a post–tooth extraction oral environment sus-
ceptible to neutrophil tissue injury(55) and major histocompat-
ibility complex–unrestricted cytotoxicity by gd T cells,(56) leading
to localized osteonecrosis and prolonged exposure of the
affected jawbone to the oral cavity through PEH (Fig. 5).
In conclusion, this article reports the successful development
of ONJ lesions in rats under the confluence of three factors:
(1) intravenous injections of ZOL, (2) tooth extraction wounding,
and (3) predisposing vitamin D deficiency. We contend that our
characterization of the disorder by gross anatomic observation
and more precise lesional phenotyping by histology, mCT, and
mPET provides convincing, clinically relevant evidence that the
rat ONJ lesion closely mirrors human disease. We also posit that
this rat model should be useful in dissecting the pathophysio-
logic mechanism(s) underpinning ONJ in humans. Furthermore,
outcomes of our animal study suggest that patients susceptible
to ONJ may be those with acquired or inherited disorders that
compromise vitamin D synthesis, metabolism, or action in the
realm of skeletal homeostasis and innate immunity.
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